University of Virginia
Welcome,         Profile    Billing    Logout  
 1080 Trials 
1259 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
O'Neill, Brian P
ECP EFS, NCT04477603: Impella ECP Early Feasibility Study

Active, not recruiting
N/A
100
US
Impella ECP
Abiomed Inc.
High-risk Percutaneous Coronary Intervention
10/25
10/25
ACCESS MANTA, NCT05936996: Prospective Clinical Registry Evaluating Contemporary MANTA Outcomes

Recruiting
N/A
250
Canada, US
MANTA Vascular Closure Device
Essential Medical, Inc., Essential Medical LLC a subsidiary of Teleflex, Incorporated
Femoral Arteriotomy Closure
01/25
03/25
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
NCT04482062: TRISCEND II Pivotal Trial

Active, not recruiting
N/A
1070
Europe, US
Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
06/24
12/29
SHIELD, NCT06689839: Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

Not yet recruiting
N/A
500
US
F2 Filter and Delivery System, Transcatheter Aortic Valve Replacement (TAVR)
EnCompass Technologies, Inc., Avania, Insight Medical Consulting
Aortic Stenosis Treated With TAVI, Aortic Diseases
07/26
10/26
VISTA-US, NCT05848284: Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( )

Recruiting
N/A
30
US
VDyne Transcatheter Tricuspid Valve Replacement System, VDyne System, VDyne Tricuspid System, VDyne Valve System, VDyne Valve
VDyne, Inc.
Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valvular Disorders
11/25
11/30
NCT04198870: MitraClip REPAIR MR Study

Recruiting
N/A
500
Europe, Canada, US
MitraClip™ device implantation, Mitral Valve Repair Surgery
Abbott Medical Devices
Mitral Valve Regurgitation
04/26
04/34
CORRAL-AF, NCT04684212: Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

Not yet recruiting
N/A
2931
US
LAmbre PlusTM Left Atrial Appendage Closure System, LAmbre device, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa), OAC
Brian O'Neill MD, Lifetech Scientific (Shenzhen) Co., Ltd.
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
12/29
12/34
Slingluff, Craig L
Mel-65, NCT03617328: Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Completed
1/2
33
US
6MHP, 6 melanoma helper peptide vaccine, Montanide ISA-51, polyICLC, CDX-1127, Varlilumab
Craig L Slingluff, Jr, Celldex Therapeutics
Melanoma
01/24
01/24
Mel66, NCT04364230: Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Completed
1/2
22
US
6MHP, 6 melanoma helper peptide vaccine, NeoAg-mBRAF, BRAF 585-614 (V600E), PolyICLC, CDX-1140
Craig L Slingluff, Jr, Celldex Therapeutics
Melanoma, Ocular Melanoma, Uveal Melanoma
03/24
03/24
AM-003, NCT04116320: Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors

Active, not recruiting
1
5
US
Echopulse, Focused Ultrasound Ablation, FUSA, Poly ICLC, Hiltonol, Standard of Care PD-1 Therapy
Craig L Slingluff, Jr, Theraclion
Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Urothelial Carcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Microsatellite Instability High, Gastric Cancer, Esophageal Cancer
02/24
02/24
McCarthy, Philip L
NCT03925532: Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Completed
2
30
US
Denosumab, AMG 162, AMG-162, Prolia, Xgeva
Roswell Park Cancer Institute, Amgen
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Osteopenia, Osteoporosis
11/22
11/22
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
Dreicer, Robert
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NKT2152-202, NCT05935748: Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Active, not recruiting
2
172
US
NKT2152, palbociclib, IBRANCE®, sasanlimab
NiKang Therapeutics, Inc., Pfizer
CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Neoplasms, Carcinoma, Renal Cell, Neoplasms, Glandular and Epithelial, Neoplasm by Histology, Adenocarcinoma, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Urologic Diseases
06/25
06/26
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting
2
70
US
Olaparib, Lynparza, Abiraterone Acetate, Prednisone
Northwestern University, AstraZeneca, National Cancer Institute (NCI)
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
12/26
01/27
NCT05617040: Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Active, not recruiting
1/2
144
US
ChAdOx1-PCAQ, MVA-PCAQ
Barinthus Biotherapeutics
Prostate Cancer
08/26
04/27
Manning, Carol A
NCT03512301: CAMCI: Advancing the Use of Computerized Screening in Healthcare

Completed
N/A
773
US
CAMCI, CAMCI task battery
Psychology Software Tools, Inc., National Institute on Aging (NIA)
Cognitive Dysfunction, Cognitive Impairment, Cognitive Decline, Cognitive Change
05/23
05/23
Borish, Larry
NCT04380038: Viral Infection in Asthma (VIA) Study

Recruiting
4
60
US
Dupilumab Injectable Product, Rhinovirus
University of Virginia, Regeneron Pharmaceuticals
Asthma
05/25
01/26
NCT05094570: Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

Recruiting
4
20
US
Dupilumab Prefilled Syringe, DUPIXENT
University of Virginia, Regeneron Pharmaceuticals
Nasal Polyps, Staphylococcus Aureus
06/24
12/24
NCT03968211: Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency

Completed
1
37
US
Salmonella typhi polysaccharide vaccine, Typhim Vi
University of Virginia, CSL Behring, Jeffrey Modell Foundation
Immune Deficiency
12/23
12/23
Jones, Robert
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Recruiting
2/3
30
Europe
Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic
10/29
10/29
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting
2/3
30
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm
10/29
10/29
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting
2/3
30
Europe
Atezolizumab, Tecentriq
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma
10/29
10/29
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

Recruiting
2/3
30
Europe
Alectinib, Alecensa
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma
10/29
10/29
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

Recruiting
2/3
30
Europe
Entrectinib, Rozlytrek
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma
10/29
10/29
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
332
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
11/26
05/28
FAKTION, NCT01992952: Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

Checkmark From P1b/2 FAKTION trial for advanced ER+/HER2- breast cancer at ASCO 2019 [screenshot]
Jun 2019 - Jun 2019: From P1b/2 FAKTION trial for advanced ER+/HER2- breast cancer at ASCO 2019 [screenshot]
Active, not recruiting
1b/2
149
Europe
AZD5363, Placebo, Fulvestrant
Velindre NHS Trust, AstraZeneca, Cenduit LLC, Covance, Cardiff and Vale University Health Board
Estrogen Receptor Positive Breast Cancer
03/19
12/23
NCT04630262: ATTUNE Cementless FB Tibial Base Clinical Study

Terminated
N/A
80
US
ATTUNE Cementless CR Fixed Bearing, ATTUNE Cementless PS Fixed Bearing
DePuy Orthopaedics
Osteoarthritis of the Knee
03/23
03/23
WAVE, NCT04540302: The Merit WRAPSODY AV Access Efficacy Study

Active, not recruiting
N/A
357
Europe, Canada, US, RoW
Merit WRAPSODY Endovascular Stent Graft, PTA
Merit Medical Systems, Inc.
Venous Stenosis, Venous Occlusion
02/24
01/26
Mossie-GO, NCT06232954: Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda

Recruiting
N/A
5600
RoW
Mossie-Go containing treated transfluthrin disc, Mossie-Go containing untreated blank disc
Africa Power Limited, Malaria Consortium, ARCTECH INNOVATION LIMITED
Malaria, Mosquito-Borne Disease
09/25
09/25
WRAP, NCT05062291: Merit SODY™ Endoprosthesis for Treatment of Stenosis or Occlusion

Recruiting
N/A
500
Europe, RoW
Merit WRAPSODY Endovascular Stent Graft
Merit Medical Systems, Inc.
Venous Stenosis, Venous Occlusion
12/25
07/27
NCT04907240: Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry

Recruiting
N/A
614
Europe
GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
W.L.Gore & Associates
Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms, Trauma Injury
10/26
10/35
O'Connor, Owen A
NCT03240211: Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Recruiting
1
37
US
Pembrolizumab, Keytruda, Pralatrexate, Folotyn, Decitabine, Dacogen
University of Virginia, Merck Sharp & Dohme LLC, Otsuka Pharmaceutical Development & Commercialization, Inc.
PTCL, CTCL
06/25
12/25
Saver, Jeffrey
EMAGINE, NCT05044507: The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "" STUDY)

Completed
N/A
100
US
BQ 2.0, BQ 2.0 sham stimulation group, BQ 2.0 active stimulation group
BrainQ Technologies Ltd.
Ischemic Stroke
11/23
01/24
NCT06386874: EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment

Recruiting
N/A
122
US
Q Therapeutic System (BQ 3.0) - Sham, BQ 3.0 Sham Stimulation Group, Q Therapeutic System (BQ 3.0) - Active, BQ 3.0 Active Stimulation Group Interventions
BrainQ Technologies Ltd.
Ischemic Stroke
07/26
10/26
Cox, Daniel J
GEM, NCT05766735: Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: a Paradigm Shift in Lifestyle Modification

Recruiting
N/A
200
US
Routine Care + Glycemic Excursion Minimization (RC+GEM), Glucose Everyday Matters, Routine Care (RC)
Chiara Fabris, PhD, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), DexCom, Inc.
Type 2 Diabetes
01/27
01/27
Gupta, Pankaj
NCT04747236: Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Recruiting
2
50
US
Azacytidine, Vidaza, Romidepsin, Istodax, Belinostat, Beleodaq, Pralatrexate, Folotyn, Gemcitabine, Gemzar
University of Virginia, Celgene
PTCL
06/26
06/28
OUTREACH, NCT03293147: Urine Analysis and Antihypertensive Treatment

Completed
N/A
200
Europe
HPLC-MS/MS-guided intervention, Standard care
University of Manchester, British Heart Foundation, Manchester Academic Health Science Centre, Omron Healthcare Co., Ltd.
Hypertension, Adherence, Medication
08/23
09/23
Stage IV NSCLC, NCT06671613: Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

Not yet recruiting
N/A
66
US
FMD, Xentigen, Regular Diet Plus FMD, Regular Diet Plus Xentigen
VA Office of Research and Development, Indiana University, US Department of Veterans Affairs Cooperative Studies Program, L-Nutra Inc
Stage IV NSCLC, NSCLC, Immunotherapy, Fasting Mimicking Diet
12/29
12/30
McCarty, John
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
Eng, Cathy
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
NCT04577963: A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Active, not recruiting
1/2
112
US
Fruquintinib, HMPL-013, Tislelizumab, BGB-A317
Hutchison Medipharma Limited, BeiGene
Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer
07/24
11/24
NCT04328740: Phase 1 Study of Oral TP-1454

Active, not recruiting
1
31
US
TP-1454 monotherapy
Sumitomo Pharma America, Inc.
Advanced Solid Tumor, Anal Cancer
03/25
05/25
Hogan, William J
SER-155-001, NCT04995653: A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Completed
1
60
US
Vancomycin Pre-Treatment, Vancomycin Placebo, SER-155, SER-155 Placebo
Seres Therapeutics, Inc., Memorial Sloan Kettering Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation
07/24
07/24
Chugh, Rashmi
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
EZH-301, NCT04204941 / 2019-003648-55: Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

Checkmark Early data from P1b/3 trial for advanced epithelioid sarcoma at medical conference 2021
May 2021 - May 2021: Early data from P1b/3 trial for advanced epithelioid sarcoma at medical conference 2021
Recruiting
3
164
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Doxorubicin HCl, Tazverik®, Placebo
Epizyme, Inc.
Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma
01/29
01/30
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
06/24
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
NCT04076579: Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Active, not recruiting
2
29
US
Olaparib, Trabectedin
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC, AstraZeneca
Sarcoma, Sarcoma Metastatic
01/23
01/25
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
APOLLO 613, NCT04593758: To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Completed
1/2
16
US
CPI-613 + Hydroxychloroquine
Cornerstone Pharmaceuticals
Sarcoma, Clear Cell
03/23
03/23
NCT02584647: PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Active, not recruiting
1/2
43
US
PLX3397, No other name, Sirolimus, Rapamune
Gulam Manji, Daiichi Sankyo
Sarcoma, Malignant Peripheral Nerve Sheath Tumors
07/23
06/24
SARC037, NCT04067115: a Phase I/II Study to Evaluate the Safety of Trabectedin in Combination with Irinotecan in Ewing Sarcoma Patients

Active, not recruiting
1/2
48
US
Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy, 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging, 18F-FLT Imaging
Sarcoma Alliance for Research through Collaboration, Janssen Scientific Affairs, LLC, National Institutes of Health (NIH), National Cancer Institute (NCI)
Ewing Sarcoma
06/25
06/25
KB-0742-1001, NCT04718675: A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Active, not recruiting
1/2
280
Europe, US
KB-0742
Kronos Bio
Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma, HGSOC, Platinum Resistant High Grade Serous Ovarian Cancer
12/25
12/25
LiFFT, NCT05918640: Lurbinectedin in FET-Fused Tumors

Recruiting
1/2
56
US
Lurbinectedin
Children's Hospital of Philadelphia, Jazz Pharmaceuticals, Stand Up To Cancer
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
07/26
07/28
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting
1
250
Europe, Canada, US, RoW
ADP adoptive cell therapy
Adaptimmune
Neoplasms
04/32
04/32
Thomas, Christopher Y
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
COMPANION-002, NCT05506943: A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers

Active, not recruiting
2/3
150
US
CTX-009, Paclitaxel
Compass Therapeutics
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
07/25
12/25
SGN35-015, NCT01716806 / 2019-003982-17: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Checkmark Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Nov 2014 - Nov 2014: Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Checkmark For newly diagnosed Hodgkin's lymphoma in elderly patients
Dec 2013 - Dec 2013: For newly diagnosed Hodgkin's lymphoma in elderly patients
Checkmark Elderly chemo-intolerant Hodgkin's lymphoma patients
More
Completed
2
131
Canada, US
brentuximab vedotin, Adcetris; SGN-35, bendamustine, dacarbazine, nivolumab
Seagen Inc., Bristol-Myers Squibb
Hodgkin Disease, Peripheral T Cell Lymphoma
04/23
09/23
Jones, David R
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
TROPION-Lung12, NCT06564844: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Recruiting
3
660
Europe, Canada, Japan, US, RoW
Datopotamab Deruxtecan, Dato-DXd, DS-1062a, Rilvegostomig, AZD2936, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT
AstraZeneca, Daiichi Sankyo
Non-small Cell Lung Cancer
10/31
01/35
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study

Recruiting
3
251
Europe, Canada, Japan, US, RoW
Linerixibat
GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited
Cholestasis
02/27
02/27
J1414, NCT02259621: Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

Checkmark In adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC
May 2018 - May 2018: In adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Active, not recruiting
2
39
Canada, US
Nivolumab, BMS-936558 or MDX1106, Carboplatin, Paraplatin, Paclitaxel, Taxol, Onxal, Ipilimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Non-Small Cell Lung Cancer
10/22
10/27
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
NCT04594694 / 2018-002575-17: Study of OCA in Combination with BZF Evaluating Efficacy, Safety, and Tolerability in Participants with PBC

Active, not recruiting
2
72
Europe, RoW
Obeticholic acid, Bezafibrate 200 MG, OCA Placebo, Bezafibrate 200 mg Placebo, Bezafibrate 400 MG, Bezafibrate 400 mg Placebo, OCA, Bezafibrate
Intercept Pharmaceuticals
Primary Biliary Cholangitis
10/25
10/25
Tagawa, Scott
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
DORA, NCT03574571 / 2018-002944-10: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting
3
738
Europe, US, RoW
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Memorial Sloan Kettering Cancer Center, Bayer
Prostate Cancer
06/26
06/26
NCT04267120: Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Active, not recruiting
2
11
US
Lenvatinib, Lenvima, Lenvanix, Pembrolizumab, Keytruda, MK-3475, Research blood collection
Washington University School of Medicine, Merck Sharp & Dohme LLC
Renal Cell Carcinoma
07/24
12/25
NCT04946370: Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Recruiting
1/2
76
US
225Ac-J591, Pembrolizumab, Androgen receptor pathway inhibitor, 68Ga-PSMA-11, 68Ga-PSMA-HBED-CC
Weill Medical College of Cornell University, United States Department of Defense, Merck Sharp & Dohme LLC
Prostate Cancer
06/26
06/28
SECURE, NCT04868604: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Recruiting
1/2
44
US
64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostatic Neoplasms, Castration-Resistant
09/26
09/26
Modesitt, Susan
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated
3
20
Canada, US, RoW
Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo
Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
09/23
09/23
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
Ballen, Karen K
ALL 001, NCT03962465: Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL

Active, not recruiting
1
36
US
Inotuzumab ozogamicin, Besponsa, Prednisone Pill, Deltasone, Daunorubicin, Cerubidine, daunomycin, rubidomycin, Vincristine, Oncovin, Vincasar, Leurocristine, Cytarabine, Ara-C, Cytosar-U, Methotrexate, Otrexup, Rasuvo, Rheumatrex, Trexall, MTX, Amethopterin, Pegaspargase, Oncospar
University of Virginia, Pfizer, Vanderbilt University, University of Wisconsin, Madison, Virginia Commonwealth University
B-cell Acute Lymphoblastic Leukemia
07/23
07/26
Phillips, Lawrence H
NCT02624908: Canagliflozin-Mealtime Insulin Rescue

Active, not recruiting
4
40
US
canagliflozin, Invokana, placebo, inactive substance
Foundation for Atlanta Veterans Education and Research, Inc., Janssen Scientific Affairs, LLC
Diabetes Mellitus, Type 2
07/18
12/22
CHANGE, NCT05040087: Changing the Natural History of Type 2 Diabetes ("" Study)

Active, not recruiting
N/A
126
US
Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels
Foundation for Atlanta Veterans Education and Research, Inc., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Emory University, Abbott Diabetes Care
Type 2 Diabetes
12/25
06/26
Shaffrey, Christopher
Symphony, NCT04912674: Evaluation of ™ Posterior Cervical System for Surgical Treatment of Adult Cervical Deformity

Recruiting
N/A
100
US
Symphony OCT System
International Spine Study Group Foundation, DePuy Synthes
Cervical Deformity
07/27
07/27
CADS, NCT04194138: Complex Adult Deformity Surgery

Recruiting
N/A
500
Canada, US
Index or spine revision surgery for complex adult spinal deformity
International Spine Study Group Foundation, Medtronic, Globus Medical Inc, SI-BONE, Inc.
Adult Spinal Deformity, Scoliosis, Kyphosis, Sagittal Imbalance
12/31
07/32
PCD 2, NCT04194996: Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study 2.0

Recruiting
N/A
200
US
Surgical intervention
International Spine Study Group Foundation, DePuy Synthes, Orthofix Inc.
Cervical Deformity
12/32
07/33
NCT04888104: Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients

Recruiting
N/A
225
US
Index or revision spine surgery for complex adult spinal deformity, VersaTie System
International Spine Study Group Foundation, NuVasive
Adult Spinal Deformity, Scoliosis, Kyphosis
12/34
12/34
Kim, John
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
795
US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, T2D
07/24
07/24
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Active, not recruiting
3
520
Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Type 2 Diabetes
04/25
04/25
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
NEPTUNE-17, NCT05838755: A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Active, not recruiting
2
145
Europe, Canada, Japan, US, RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
10/24
01/25
Hall, Richard I
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
06/25
02/26
NCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2/3
950
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Pemetrexed, Alimta, Paclitaxel, Carboplatin, Paraplatin, Cisplatin, Platinol, Placebo
Regeneron Pharmaceuticals
Non-small Cell Lung Cancer
01/30
12/31
R3767-ONC-2235, NCT05785767: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Hourglass Nov 2024 - Dec 2024 : Initial data from trial in combination with Libtayo for advanced NSCLC
Recruiting
2/3
850
Canada, US, RoW
fianlimab, REGN3767, cemiplimab, REGN2810, Libtayo, Placebo
Regeneron Pharmaceuticals
Advanced Non-Small Cell Lung Cancer
03/30
02/32
RAMOSE, NCT03909334: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
2
160
US
Osimertinib, Tagrisso, Ramucirumab, Cyramza
Xiuning Le, M.D. Anderson Cancer Center, Eli Lilly and Company
Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
09/25
10/25
BTCRC-LUN19-396, NCT04367311: Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Recruiting
2
100
US
Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Nasser Hanna, Genentech, Inc.
Lung Cancer, NSCLC
09/25
01/26
BTCRC-LUN18-153, NCT04317534: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Recruiting
2
244
US
Pembrolizumab
Greg Durm, MD, Merck Sharp & Dohme LLC
NSCLC, Stage I
04/26
04/29
Hill, Michael D
PLATINUM, NCT04443608: Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

Terminated
4
115
US
Patiromer Powder for Oral Suspension [Veltassa], Active drug, Placebo, Inactive substance
Comprehensive Research Associates
Hyperkalemia
03/23
06/23
ESCAPE-NEXT, NCT04462536 / 2020-002360-30: Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Completed
3
850
Europe, Canada, US, RoW
Placebo, Nerinetide, NA-1
NoNO Inc., University of Calgary
Stroke, Acute
08/23
08/23
NCT05123755: Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

Recruiting
2a
120
US
AV-001 Injection, AV-001 Placebo Injection
Vasomune Therapeutics, Inc.
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral, Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
12/24
03/25
KOURAGE, NCT06374797: A Study of Auxora in Patients with AKI and Injurious Lung "Crosstalk"

Recruiting
2
150
US
Auxora, Placebo
CalciMedica, Inc.
Acute Kidney Injury
08/25
08/25
 

Download Options